Track OraSure Technologies, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

OraSure Technologies, Inc. OSUR Open OraSure Technologies, Inc. in new tab

3.08 USD
P/E
12.42
EPS
-0.94
P/B
0.62
ROE
-18.30
Beta
0.86
Target Price
5.00 USD
OraSure Technologies, Inc. logo

OraSure Technologies, Inc.

🧾 Earnings Recap – Q3 2025

OraSure Technologies reported Q3 2025 total revenues of $27.1 million, reflecting a strategic repositioning amid mixed market conditions, while also highlighting a significant acquisition aimed at expanding their diagnostic portfolio.

  • Total revenue for Q3 2025 was $27.1 million, driven by Diagnostics revenues of $14.5 million and Sample Management revenues of $10.3 million.
  • The company signed a definitive agreement to acquire BioMedomics, adding a rapid test for sickle cell disease to its international diagnostic portfolio.
  • U.S. Diagnostics revenue anticipated to decline slightly, while International Diagnostics expected to see a 20% year-over-year reduction, reflecting funding challenges in public health.
  • The renewal of the "Together Take Me Home" program aims to further support HIV self-testing initiatives, contributing an expected $1.8 million in revenue for Q4.
  • Confidence remains for 2026 growth, particularly in Sample Management, driven by advancements in genomics and increased adoption in international markets.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 5, 2026
P/E12.42
EPS-0.94
Book Value4.84
Price to Book0.62
Debt/Equity3.87
% Insiders6.737%
Growth
Revenue Growth-0.29%
Estimates
Forward P/E-6.38
Forward EPS-0.47
Target Mean Price5.00

DCF Valuation

Tweak assumptions to recompute fair value for OraSure Technologies, Inc. (OSUR)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

OraSure Technologies, Inc. Logo OraSure Technologies, Inc. Analysis (OSUR)

United States Health Care Official Website Stock

Is OraSure Technologies, Inc. a good investment? OraSure Technologies, Inc. (OSUR) is currently trading at 3.08 USD. Market analysts have a consensus price target of 5.00 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 12.42. This relatively low multiple may signal that OraSure Technologies, Inc. is undervalued compared to historical market norms.

Earnings Schedule: OraSure Technologies, Inc. is expected to release its next earnings report on May 5, 2026. The market consensus estimate for Forward EPS is -0.47.

Investor FAQ

Does OraSure Technologies, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is OraSure Technologies, Inc.?

OraSure Technologies, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 5, 2026. The company currently has a trailing EPS of -0.94.

Company Profile

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.

Exchange Ticker
NMS (United States) OSUR
FRA (Germany) EP3.F
Historical Dividends
Year Total Dividends
1998 1.60 USD

Yearly aggregated dividends

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
April 8, 1987 3.000000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion